Stocks Ride
Kazia Therapeutics (KZIA) Stock Gains Market Traction On Early-Stage Trial Progress
Kazia Therapeutics Limited (NASDAQ: KZIA) shares surged 20.29% to $8.21 as of the latest check, driven by encouraging early clinical data from its Phase 1b trial. Impressive Early Efficacy In the first patient treated with a combination of paxalisib, pembrolizumab